Erasmus JJ et al. – This article reviews the use of positron emission tomography (PET) in patients with these uncommon lung neoplasms as well as radiotracers that have been developed to interrogate different metabolic pathways, receptors, and targets to overcome the potential limitations of FDG–PET in the diagnosis, staging, as well as early response evaluation and monitoring of response to targeted therapies.
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor